StreetAlpha.app
Home › Stocks › CGEM

Cullinan Therapeutics, Inc. (CGEM)

Healthcare
$8.89
▼ −1.98%
LAST CLOSE · NOV 20

Cullinan Therapeutics develops bispecific T cell engager therapies for autoimmune diseases and cancer. It last closed at $8.89 on Nov 20, down 1.98% on the day. The next earnings report for CGEM is expected around Tue, Mar 9, 2027. Over its last 8 reports the stock moved an average of 3.1% the session after earnings. Over the last 12 months CGEM insiders bought $0 of stock on the open market and sold $2.6M, according to SEC Form 4 filings.

AI Auto Pilots
Is CGEM in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CGEM.

Key Stats

Last 12 months
Results
Net income
−$203.5M
Free cash flow
−$165.5M
Valuation
Market cap
$577.1M
64.9M shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$88.3M
At Sep 30
Shares outstanding
64.9M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$67.5M−$67.5MFY2021FY2022: $109.2M$109.2MFY2022FY2023: −$155.1M−$155.1MFY2023FY2024: −$167.6M−$167.6MFY2024FY2025: −$219.9M−$219.9MFY2025

From CGEM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Mar 9
Estimated date · Time not announced
Reported EPS
—
Not on file yet
Year ago EPS
—
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Not enough quarters on file yet.
How CGEM moved after its last 8 reports
Average move the session after a report ±3.1%
Nov 10, 2026Time not announced−4.3%
Aug 6, 2026Time not announced+1.9%
May 7, 2026Time not announced−1.8%
Mar 10, 2026Time not announced−2.6%
Jan 8, 2026Time not announced+1.8%
Nov 6, 2025Time not announced+0.6%
Aug 7, 2025Time not announced−10.8%
May 8, 2025Time not announced+0.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CGEMStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CGEM
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CGEM

Technical Analysis

CGEM · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 36% below its 20 day and 65% below its 50 day average. It is 77% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 26), oversold. The nearest support is the Pivot S1 at $8.64, and the nearest resistance the Pivot at $9.05.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 11.7%/day
Key levels
$23.1952 week high+160.9%
$17.01100 day average+91.3%
$15.74200 day average+77.1%
$15.32Swing high (Oct 22)+72.3%
$14.6550 day average+64.8%
$12.0620 day average+35.7%
$9.30Pivot R1+4.6%
$9.05Pivot+1.8%
$8.89Last close
$8.64Pivot S1−2.8%
$8.4752 week low−4.7%
$8.47Swing low (Nov 17)−4.7%
Indicators
RSI (14)26.37Oversold below 30Oversold
MACD-1.72Below its signal lineBearish
Stochastic6.7Near the bottom of its rangeOversold
ADX (14)36.1Trending down
Williams %R-94.6Oversold below −80, overbought above −20Oversold
CCI (20)-92.9Oversold below −100, overbought above 100Neutral
Rate of change−21.4%Change over 10 sessionsBearish
ATR (14)$1.04Typical daily range, 11.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CGEM

What happened before

See how CGEM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CGEM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CGEM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CGEMHow many large options trades hit CGEM, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CGEM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●85 buying vs 77 selling
  • ▼Held by funds -2.2 pts
  • ▼Funds holding -2
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding182184−1.1%
In funds' top 10330.0%
Held by funds108.2%110.5%−2.3 pts
New / increased21 / 6429 / 84−24.8%
Reduced / sold out55 / 2247 / 20+14.9%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CGEM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CGEM Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$2.6M25 sales · 5 insiders
64% of the selling was under pre-arranged trading plans.
2025-12 sold $258K2026-01 sold $49K2026-02 sold $988K2026-03 sold $125K2026-05 sold $117K2026-07 sold $143K2026-08 sold $608K2026-09 sold $173K2026-11 sold $49KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 5Jennifer MichaelsonChief Scientific OfficerSale plan4,000$12.36$49K
Sep 8Jennifer MichaelsonChief Scientific OfficerSale plan8,000$21.57$173K
Aug 13Jennifer MichaelsonChief Scientific OfficerSale plan30,000$20.26$608K
Jul 6Jennifer MichaelsonChief Scientific OfficerSale plan8,000$17.82$143K
May 5Jennifer MichaelsonChief Scientific OfficerSale plan8,000$14.62$117K
Mar 5Jennifer MichaelsonChief Scientific OfficerSale plan8,000$15.68$125K
Every insider buy and sale for CGEM over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CGEM insider trades →

From SEC Form 4 filings by CGEM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CGEM is in one of them and how their past CGEM trades turned out.

CGEM in the AI portfolios
Loading…

CGEM News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CGEM in an article yet. Here's the latest on the wider market.

CGEM in the news

About Cullinan Therapeutics

Cullinan Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, that develops drug candidates for autoimmune diseases and cancer. Its main programs are bispecific T cell engagers, a type of antibody therapy designed to direct immune T cells against target cells. The company is testing these candidates in clinical trials for lupus, rheumatoid arthritis, Sjögren's disease, and acute myeloid leukemia, and it also works with a partner on an oral lung cancer treatment. Its target patients are people living with these conditions.

Headquarters
Cambridge, MA